Upper Tract Urothelial Carcinoma Clinical Trial
Official title:
Prospective Clinical Trial of the Feasibility and Safety of Extraperitoneal Laparoscopic Extended Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Upper Tract Urothelial Carcinoma
Extended pelvic lymph node dissection in bladder carcinoma provides staging and, in selected patients, a survival benefit. Recent studies showed the therapeutic benefit of retroperitoneal lymph node dissection (RPLND) in advanced stage of upper tract urothelial carcinoma (UTUC). Also laparoscopic extended RPLND is still a technical challenge in urology, considering the high rate of severe complications and difficulties in manipulation. In Renji Hospital, laparoscopic extended RPLND at time of nephroureterectomy was performed via an extraperitoneal approach, avoiding interference with abdominal organs and achieving better exposure.The aim of the present study was to determine the safety and feasibility of performing an extraperitoneal laparoscopic extended RPLND at the time of radical nephroureterectomy (RNU) for UTUC in a prospectively collected cohort of patients.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | March 31, 2019 |
Est. primary completion date | December 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 80 Years |
Eligibility |
Inclusion Criteria: - clinically diagnosed with upper tract urothelial carcinoma - have no distant metastasis - have an ECOG 0 to 2 - expected to receive radical nephroureterectomy Exclusion Criteria: - had no previous abdominal surgeries - contra-indications to laparoscopic surgery (e.g. severe chronic obstructive pulmonary disease) - patients with cT4 disease before surgery |
Country | Name | City | State |
---|---|---|---|
China | Renji Hospital, School of Medicine, Shanghai Jiao Tong University | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
RenJi Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Perioperative complications rate | Perioperative complications were evaluated up to 90 days after surgery, and were graded by Clavien-Dindo classi?cation. | 90 days | |
Secondary | Operating time | Operating time | during surgery | |
Secondary | Estimate blood loss | Estimate blood loss during surgery | during surgery | |
Secondary | length of stay | The length of hospital stay | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02547350 -
Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas
|
Phase 2 | |
Recruiting |
NCT04948528 -
Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection
|
||
Recruiting |
NCT05917158 -
A Study of RC48-ADC Combined With JS001 For Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma
|
Phase 2 | |
Recruiting |
NCT02923557 -
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients
|
Phase 2 | |
Recruiting |
NCT02969083 -
Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma
|
Phase 2 | |
Recruiting |
NCT03230201 -
Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma)
|
N/A | |
Recruiting |
NCT02740426 -
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03617003 -
Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)
|
Phase 1 |